# US 2010/0167301 A1 · Method and device for immunoassay using nucleotide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167301 A1
- Document ID: US20100167301A1
- Status: Published application
- Kind: A1
- Application number: 12/650,241
- Filed: 2009-12-30
- Published: 2010-07-01
- Earliest claimed: 2008-12-31
- Assignees: Abbott Point of Care Inc.
- Inventors: Gordon Bruce Collier; Cary James Miller
- Web page: https://patentgrep.com/patent/US20100167301A1

## CPC

- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/5302: {Apparatus specially adapted for immunological test procedures}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences.

## Claims

### Claim 1

A single-use cartridge for performing an immunoassay, comprising:
a sample entry port for receiving a biological sample suspected of containing a target analyte,
a conduit containing an electrode,
a region containing a wash fluid, and
a waste chamber,
wherein an immunoassay is formed on said electrode, the immunoassay comprising immobilized first antibody bound to said target analyte, second antibody to said target analyte, wherein the second antibody is attached to a first single stranded nucleotide; and
one or more signal elements each attached to a second single stranded nucleotide having complimentary base pairs to the first single stranded nucleotide;
wherein the wash fluid is capable of washing said biological sample from said electrode in said conduit into said waste chamber.

### Claim 2 (depends on 1)

The cartridge of claim 1, wherein the one or more signal elements comprise a non-enzymatic detection moiety that is selected from the group consisting of fluorescent, colorimetric, and radioactive elements.

### Claim 3 (depends on 1)

The cartridge of claim 1, wherein the one or more signal elements comprise one or more signal enzymes, the cartridge further comprising:
a region containing an enzyme substrate,
wherein said enzyme substrate is capable of reacting with said one or more signal enzymes to generate a signal at said electrode proportionate to the amount of said target analyte in said biological sample.

### Claim 4 (depends on 3)

The cartridge of claim 3, wherein the first antibody binds to a first epitope of the target analyte.

### Claim 5 (depends on 3)

The cartridge of claim 3, wherein the second antibody binds to a second epitope of the target analyte.

### Claim 6 (depends on 3)

The cartridge of claim 3, wherein the one or more signal enzymes are selected from the group consisting of alkaline phosphatase, glucose oxidase, lactate oxidase, urease, horseradish peroxidase, galactose oxidase, and beta-galactosidase.

### Claim 7

A composition of matter for use in an immunoassay comprising:
a FAB fragment covalently linked to a first nucleotide; and
one or more signal elements each covalently linked to a second nucleotide,
wherein said first nucleotide has one or more repeated sequences, and wherein the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the FAB fragment to the signal element is controlled by the number of repeated sequences.

### Claim 8 (depends on 7)

The composition of matter according to claim 7, wherein the one or more signal elements comprise a non-enzymatic detection moiety that is selected from the group consisting of fluorescent, colorimetric, and radioactive elements.

### Claim 9 (depends on 7)

The composition of matter according to claim 7, wherein the one or more signal elements comprise one or more signal enzymes.

### Claim 10 (depends on 9)

The composition of matter according to claim 9, wherein the first nucleotide and second nucleotide contain a coupling moiety at the 5′ end, 3′ end or internal to the nucleotide sequence.

### Claim 11 (depends on 10)

The composition of matter according to claim 10, wherein the coupling moiety is generated from a modified phosphoramidite selected from the group consisting of an amino modifier, thiol modifier, and dithiol.

### Claim 12 (depends on 9)

The composition of matter according to claim 9, wherein the 3′-end or 5′-end of the synthetic oligonucleotide is protected from endogenous exonuclease activity in the sample by incorporating a protective chemical group.

### Claim 13 (depends on 12)

The composition of matter according to claim 12, wherein the protective chemical group is a phosphorothioate.

### Claim 14 (depends on 9)

The composition of matter according to claim 9, wherein the one or more signal enzymes are selected from the group consisting of alkaline phosphatase, glucose oxidase, lactate oxidase, urease, horseradish peroxidase, galactose oxidase, and beta-galactosidase.

### Claim 15 (depends on 9)

The composition of matter according to claim 9, wherein the first nucleotide has at least three repeated sequences which bind to at least three of the second sequences of at least three of the one or more signal enzymes.

### Claim 16 (depends on 9)

The composition of matter according to claim 9, wherein the first nucleotide has at least five repeated sequences which bind to at least five of the second sequences of at least three of the one or more signal enzymes.

### Claim 17

A method of determining the presence of analyte in a biological sample comprising:
contacting the biological sample so that the analyte binds to an immobilized first antibody and a second antibody to form an immunoassay, wherein the second antibody is bounded to at least one signal enzyme via a synthetic nucleotide bridge;
washing said biological sample from said immunoassay; and
determining the presence of the analyte based on a signal generated by a reaction with the signal enzyme.

### Claim 18

A method of determining whether a patient may suffer a myocardial infarction comprising:
(a) applying a sample from a patient to a surface to which is bound a first antibody which is capable of binding to a first epitope on cTnI;
(b) adding a second antibody that is capable of binding to a second epitope on cTnl, wherein the second antibody further comprises a first stranded polynucleotide sequence that is bound to one or more second stranded polynucleotides bound to a signal element; and
(c) determining the extent of binding of the second antibodies.

### Claim 19 (depends on 18)

The method of claim 18, wherein the signal element comprises a signal enzyme.

### Claim 20 (depends on 18)

The method of claim 18, wherein the patient has not suffered a myocardial infarction prior to step (a).

### Claim 21

A signal conjugate batch comprising signal conjugates in which at least 80 mol % of the signal conjugates have from about 2 to about 20 signal elements per signal conjugate.

### Claim 22 (depends on 21)

The signal conjugate batch of claim 21, in which at least 80 mol % of the signal conjugates have from about 5 to about 10 signal elements per signal conjugate.

### Claim 23

A signal conjugate batch comprising signal conjugates in which at least 80 mol % of the signal conjugates have from about 1 to about 4 signal antibodies per signal conjugate.

### Claim 24 (depends on 23)

The signal conjugate batch of claim 23, in which at least 80 mol % of the signal conjugates have about 2 signal antibodies per signal conjugate.

### Claim 25

A signal conjugate batch comprising signal conjugates in which at least 80 mol % of the signal conjugates have a molar ratio of signal elements to signal antibodies ranging from about 0.5 to about 20.

### Claim 26 (depends on 25)

The signal conjugate batch of claim 25, in which at least 80 mol % of the signal conjugates have a molar ratio of signal elements to signal antibodies ranging from about 0.5 to about 5.
